Skip to content
POM-V Prescription Required Companion Animal

Vetmedin Chew 1.25 mg Chewable Tablets for Dogs

Active ingredient: Pimobendan

Form

Chewable

Species

Dogs

Manufacturer

Boehringer Ingelheim Vetmedica GmbH

VMD MA No.

61700/3023

What it's used for

For the treatment of dilated cardiomyopathy in the preclinical stage (asymptomatic with an increase in left ventricular end-systolic and end-diastolic diam...

Full indications, dosage and side effects ↓
View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Pimobendan

  1. 1

    Ask your vet for a written prescription

    They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.

  2. 2

    Fill it at a registered online retailer

    The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Vetmedin Chew 1.25 mg Chewable Tablets for Dogs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

For the treatment of dilated cardiomyopathy in the preclinical stage (asymptomatic
with an increase in left ventricular end-systolic and end-diastolic diameter) in
Doberman Pinschers following echocardiographic diagnosis of cardiac disease.
For the treatment of dogs with myxomatous mitral valve disease (MMVD) in the
preclinical stage (asymptomatic with a systolic mitral murmur and evidence of
increased heart size) to delay the onset of clinical symptoms of heart failure.
To ensure a correct dosage, body weight should be determined as accurately as
possible.
A dosage range of 0.2 mg to 0.6 mg pimobendan/kg body weight, divided into two
daily doses, should be respected.
The preferable daily dose is 0.5 mg pimobendan/kg body weight, divided into two
daily doses (0.25 mg/kg bodyweight each) approximately 12 hours apart.
For a body weight of 5 kg, this corresponds to one 1.25 mg chewable tablet in the
morning and one 1.25 mg chewable tablet in the evening.
1.25 mg
chewable tablet
2.5 mg chewable
tablet
5 mg chewable
tablet
10 mg chewable
tablet
Body
weight
Morning EveningMorning EveningMorning EveningMorning Evening5 kg1110 kg1120 kg1140 kg11
Do not exceed the recommended dosage.
Administration of pimobendan should take place approximately one hour before
feeding.
Pimobendan may also be used in combination with a diuretic, e.g. furosemide or
torasemide.
To allow accurate dosing according to body weight, the chewable tablet can be
halved along the designated score line.
Do not use pimobendan in hypertrophic cardiomyopathies or in diseases in which
an improvement in cardiac output cannot be achieved for functional or anatomical
reasons (e.g. aortic stenosis).
Since pimobendan is metabolised mainly via the liver, it should not be used in dogs
with severe impairment of liver function.
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
Dogs:
Rare
(1 to 10 animals / 10,000
animals treated):
- Vomiting
, diarrhoea
- Anorexia
, lethargy
- Increased heart rate
1,3
,

increase in mitral valve
regurgitation
Very rare
(< 1 animal / 10,000 animals
treated, including isolated
reports):
- Mucosa petechiae
, haemorrhage
(subcutaneous)
These effects are dose-dependent and can be avoided by reducing the dose.
Transient
Due to a slight positively chronotropic effect.
Observed during chronic pimobendan treatment in dogs with mitral valve
disease.
A relationship with pimobendan has not been clearly established, signs
disappear when the treatment is withdrawn.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian,
to either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.
The veterinary medicinal product has not been tested in cases of asymptomatic
DCM in Dobermans with atrial fibrillation or sustained ventricular tachycardia.
The veterinary medicinal product has not been tested in cases of asymptomatic
myxomatous mitral valve disease in dogs with significant supraventricular and/or
ventricular tachyarrhythmia.

Special precautions for safe use in the target species:
The blood glucose should be tested regularly during treatment in dogs with existing
diabetes mellitus.
For use in the preclinical stage of dilated cardiomyopathy (asymptomatic with an
increase in left ventricular end-systolic and end-diastolic diameter), a diagnosis
should be made by means of a comprehensive cardiac examination (incl.
echocardiographic examination and possibly Holter monitoring).
For use in the preclinical stage of myxomatous mitral valve disease (stage B2,
according to ACVIM consensus: asymptomatic with mitral murmur ≥
cardiomegaly due to myxomatous mitral valve disease), a diagnosis should be
made by means of a comprehensive physical and cardiac examination which should
include echocardiography or radiography where appropriate.
Monitoring of cardiac function and morphology is recommended in animals treated
with pimobendan.
The chewable tablets are flavoured. In order to avoid any accidental ingestion, store
tablets out of reach of animals.
Special precautions to be taken by the person administering the veterinary
medicinal product to animals:
Wash hands after use.
To avoid accidental ingestion of the veterinary medicinal product by a child, divided
or unused tablets should be returned to the open blister pocket and placed back in
the cardboard box.
In case of accidental ingestion, seek medical advice immediately and show the
package leaflet or the label to the physician.
Advice to doctors: accidental ingestion, especially by a child, may lead to the
occurrence of tachycardia, orthostatic hypotension, flushing of the face and
headaches.
Special precautions for the protection of the environment:
Not applicable.
In pharmacological studies no interaction between the cardiac glycoside ouabain
(strophanthin) and pimobendan was observed. The pimobendan-induced increase
in cardiac contractility is attenuated by the calcium antagonists verapamil and
diltiazem and by the β-antagonist propranolol.
Do not store above 25 °C.
Divided tablets should be returned to the open blister pocket and placed back in the
cardboard box.
Not applicable.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.

Medication costs adding up?

Pet insurance can cover prescription medications. Find the right policy for your pet.

Compare insurance

Find cheaper vets near you

Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.